Innate Pharma SA
SWB:IDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
SWB:IDD
|
FR |
|
Covivio SA
F:F5D0
|
FR |
|
D
|
Deutsche Grundstuecksauktionen vormals Berliner Grundstuecksauktionen AG
XMUN:DGR
|
DE |
|
Telesia SpA
MIL:TLS
|
IT |
|
W
|
WuXi AppTec Co Ltd
F:WX8
|
CN |
|
Nihon Parkerizing Co Ltd
TSE:4095
|
JP |
|
Altamir SCA
PAR:LTA
|
FR |
|
infas Holding AG
F:IFS
|
DE |
|
RenovoRx Inc
NASDAQ:RNXT
|
US |
|
Cobalt Blue Holdings Ltd
F:COH
|
AU |
|
A
|
Anand Rayons Ltd
BSE:542721
|
IN |
|
Scala Inc
TSE:4845
|
JP |
|
E
|
Esi SpA
MIL:ESI
|
IT |
|
Honat Bancorp Inc
OTC:HONT
|
US |
Wall St Price Targets
IDD Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IDD is 5.445 EUR with a low forecast of 4.535 EUR and a high forecast of 6.496 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IDD's stock price target?
Price Target
5.445
EUR
According to Wall Street analysts, the average 1-year price target for IDD is 5.445 EUR with a low forecast of 4.535 EUR and a high forecast of 6.496 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 088%
The compound annual growth rate for Gross Profit over the next 3 years is 1 088%.
